Loading stock data…
Johnson & Johnson (JNJ)
$255.41+0.75 (+0.30%)
Market OpenUpdated 11:03 AM EDT
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Johnson & Johnson in the Healthcare sector is trading at $254.66 with a market capitalization of $549.8B. Wall Street consensus targets $257.50 (22 analysts), implying a +1.1% move over the next 12 months. The stock is currently near its 52-week high of $255.11, remaining 18.3% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $24.06B↓ | $24.56B↑ | $23.99B↑ | $23.74B↑ | $21.89B |
| Gross Profit | $15.96B↓ | $16.60B↓ | $16.69B↑ | $16.11B↑ | $14.54B |
| Operating Income | $6.39B↑ | $5.59B↓ | $7.10B↑ | $6.71B↑ | $6.20B |
| Net Income | $5.24B↑ | $5.12B↓ | $5.15B↓ | $5.54B↓ | $11.00B |
Peer Comparison
UNHPFEABBV
Fundamentals
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative M...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$549.78B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
26.46
Beta
Defensive asset. Lower volatility than the S&P 500.
0.26
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.05%
ROE
Elite ROE. Management converts capital into profit efficiently.
25.92%
Volume
Today's trading volume
2.04M
Recent News
Florida, Pennsylvania, Or California? Which Retiree Keeps The Most Money?
Three retirees own the same portfolio. Each holds $1 million in dividend-paying stocks generating roughly $60,000 a year of income. One lives in Florida, one in Pennsylvania, and one in California. By the time the year ends, they will not have the same amount of spending power, even though their brokerage statements look identical. State ... Florida, Pennsylvania, Or California? Which Retiree Keeps The Most Money?
Here’s How You Can Retire In America’s Pickleball Capital
Pickleball has become the fastest-growing sport in America, and retirees helped fuel the boom. The game is easy to learn, relatively gentle on aging joints, highly social, and dramatically cheaper than golf or boating. In many retirement communities, a few pickleball courts now do the work that country clubs once did, providing exercise, competition, and ... Here’s How You Can Retire In America’s Pickleball Capital
Let Your Dividends Do The Housework For You. Literally.
Financial independence rarely arrives with a parade. For many people, it shows up on a Tuesday morning when someone else is scrubbing the bathroom. Hiring a cleaning service is a luxury many retirees and busy professionals buy, not just because they hate cleaning, but because it converts money into time. A housekeeper does more than ... Let Your Dividends Do The Housework For You. Literally.
Johnson & Johnson (JNJ) Beats Lawsuit Alleging that Talc caused Three Women’s Cancer
Johnson & Johnson (NYSE:JNJ) is one of the 10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds. On June 6, Reuters reported that a Los Angeles jury found Johnson & Johnson (NYSE:JNJ) was not negligent in a lawsuit alleging its talc products led to ovarian cancer in three women. Reuters said the lawsuit […]
These Household Names Are Dividend Kings. They’re Rock-Solid For Income.
Many Kings are household names, like Coke, Pepsi, Johnson & Johnson and Procter & Gamble Over the past decade-plus, they’ve taken a back seat to tech stocks that have powered market gains. From 2014 through the end of 2025, the Kings returned 8.7% annually to the S&P 500’s nearly 14%.